Breaking News

Ziihera Now Available for HER2+ Biliary Cancer

The therapeutic antibody was developed using ProBioGen's proprietary GlymaxX technology.

Author Image

By: Charlie Sternberg

Associate Editor

Ziihera (zanidatamab-hrii), a therapeutic antibody developed using ProBioGen’s proprietary GlymaxX technology, has become commercially available. Following FDA approval late last year for the treatment of HER2-positive biliary tract cancer (BTC), this milestone represents a step forward in targeted cancer therapy. “The market availability of a bispecific therapeutic antibody developed with the GlymaxX technology represents an important milestone,” said Dr. Gabriele Schneider...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters